Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Single-application Study Evaluating and Comparing Product Adhesion in Healthy Adult Subjects Using ZTlido 1.8% Versus Salonpas(Lidocaine Patch 4%), Aspercreme(Lidocaine Patch 4%) and IcyHot(Lidocaine 4% + Menthol 1% Patch)

The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1% Patch), on the Mid to upper back while being worn for 12 hours in healthy adult human subjects.

开始日期2021-07-01

申办/合作机构

Scilex Pharmaceuticals, Inc.

100 项与薄荷脑/水杨酸甲酯相关的临床结果

登录后查看更多信息

100 项与薄荷脑/水杨酸甲酯相关的转化医学

登录后查看更多信息

100 项与薄荷脑/水杨酸甲酯相关的专利（医药）

登录后查看更多信息

项与薄荷脑/水杨酸甲酯相关的文献（医药）

2022-06-17·Recent Patents on Nanotechnology4区 · 材料科学

WITHDRAWN: Development, In Vitro and Ex-Vivo Assessment of CAP Liposomal Film for Dermal Delivery

4区 · 材料科学

Article

作者: babu, Nikhilesh ; Nimmathota, Madhavi ; Beeravelli, Sudhakar ; Murthy Kolapalli, Venkata Ramana

The article has been withdrawn at the request of the editor of the journal Recent Patents on Nanotechnology due to incoherent content. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.phpBentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

项与薄荷脑/水杨酸甲酯相关的新闻（医药）

2024-04-16

·蒲公英Ouryao

参比制剂目录（第79批）正式发布！

转自：国家药监局编辑：wangxinglai20042024年04月16日，国家药监局发布了第79批次仿制药一致性评价参比制剂目录，其中新增品种64个、变更及增加持证商品种36个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第七十九批）。涉及品种：维生素B1注射液、玛伐凯泰胶囊、醋酸钠林格葡萄糖注射液（Ⅰ）、复方水杨酸甲酯薄荷醇贴剂、右美托咪定舌下膜、富马酸伏诺拉生口崩片、伊潘立酮片、注射用伊沙匹隆、磷酸二甲啡烷糖浆、重酒石酸氢可酮缓释片、重酒石酸氢可酮缓释片、利多卡因透皮贴片、恩格列净利格列汀二甲双胍缓释片（Ⅰ）、恩格列净利格列汀二甲双胍缓释片（Ⅱ）、恩格列净利格列汀二甲双胍缓释片（Ⅲ）、恩格列净利格列汀二甲双胍缓释片（Ⅳ）、醋酸锌颗粒、氟比洛芬颗粒、诺孕曲明炔雌醇贴片等；仿制药参比制剂目录（第79批）（扫描二维码下载附件）仿制药参比制剂目录（第79批）

一致性评价上市批准

100 项与薄荷脑/水杨酸甲酯相关的药物交易

登录后查看更多信息